marketing agreement

Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.

Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.

Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.

The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.

The seven-gene test, ColonSentry, is designed to determine an individual's current risk for colorectal cancer relative to an average risk population.

The mass spec test is designed to measure blood-based proteins to predict type 2 diabetes patients' risk of developing diabetic kidney disease.

The test combines a genetic risk analysis with behavioral and lifestyle assessments, and uses  Thermo Fisher Scientific's TaqMan OpenArray for genotyping.

Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement

The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.

Guardant's lab will make Guardant360 available to doctors and their patients in the region to help identify patients eligible for molecularly targeted drugs.